![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Exact Sciences Reaches $1.7 Billion Deal to Buy Liquid Biopsy Test Developer
Exact Sciences Reaches $1.7 Billion Deal to Buy Liquid Biopsy Test Developer
![signature.gif](https://www.fdanews.com/ext/resources/test/Device_Images2/signature.gif?t=1596243440&width=430)
Exact Sciences announced that it has reached an agreement to acquire Thrive Earlier Detection, a blood-based cancer test developer, for $1.7 billion. Thrive Earlier Detection could receive as much as $2.15 billion if a blood-based, multicancer screening test hits certain milestones.
Exact Sciences intends to combine Thrive’s early-stage cancer screening test, CancerSEEK, with its own scientific platform and clinical organization, to become more competitive in the lucrative blood-based, multicancer screening market.
CancerSEEK showed promise in a 10,000-patient prospective interventional study, Exact Sciences said. An early version of the test detected 10 different types of cancer, including seven with no recommended screening guidelines.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct